Add to ORKGHuman and mouse embryonal carcinoma (EC) cells lines were compared with several cell lines of a more differentiated phenotype for their relative sensitivities to the cytotoxic effects of cis-platinum (cis-diamine-dichloroplatinum; CDDP); EC lines were among the most sensitive. Furthermore, several markers of EC cell differentiation were not induced by CDDP, irrespective of the concentration of the drug used. These data provide an explanation for the relative sensitivity of the EC cells in non-seminomatous germ-cell tumors to cis-platinum therapy
Clonogenic survival of HeLa, Chinese hamster and HaK cells after treatment with a range of cisplatin...
In an attempt to examine the cellular changes associated with cisplatin resistance, we selected a ci...
The aim of this study is to establish anti-tumour potency of the new oral platinum drug JM216 and it...
Human and mouse embryonal carcinoma (EC) cells lines were compared with several cell lines of a more...
In the embryonal carcinoma cell line Tera and its 3.7-fold cis-diamminedichloroplatinum(II) (CDDP)-r...
Cisplatin (CDDP) resistance mechanisms were studied in a model of three germ cell tumour and three c...
The potential of a combination of differentiation induction and chemotherapy was analyzed. Treatment...
A series of cis-dichloroplatinum(II) 2,3-diaminopropionamide complexes synthesised as potential imag...
Cis-Diamminedichloroplatinum(II) (CDDP) is used in the treatment of various cancers, with or without...
Apart from modulation of tumor-cell drug sensitivity, induction of differentiation might be an alter...
The clastogenicity of cisplatin, cis-diamminedichloroplatinum(II), an extensively used antitumor dru...
Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a s...
The effects of cis-dichloro-diammino-platinum(II) (cis-Pt) bound to DNA have been compared to those ...
Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin show a large inte...
The cytotoxicity of Cisplatin (CDDP) is traditionally believed to be cell cycle independent. This ge...
Clonogenic survival of HeLa, Chinese hamster and HaK cells after treatment with a range of cisplatin...
In an attempt to examine the cellular changes associated with cisplatin resistance, we selected a ci...
The aim of this study is to establish anti-tumour potency of the new oral platinum drug JM216 and it...
Human and mouse embryonal carcinoma (EC) cells lines were compared with several cell lines of a more...
In the embryonal carcinoma cell line Tera and its 3.7-fold cis-diamminedichloroplatinum(II) (CDDP)-r...
Cisplatin (CDDP) resistance mechanisms were studied in a model of three germ cell tumour and three c...
The potential of a combination of differentiation induction and chemotherapy was analyzed. Treatment...
A series of cis-dichloroplatinum(II) 2,3-diaminopropionamide complexes synthesised as potential imag...
Cis-Diamminedichloroplatinum(II) (CDDP) is used in the treatment of various cancers, with or without...
Apart from modulation of tumor-cell drug sensitivity, induction of differentiation might be an alter...
The clastogenicity of cisplatin, cis-diamminedichloroplatinum(II), an extensively used antitumor dru...
Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a s...
The effects of cis-dichloro-diammino-platinum(II) (cis-Pt) bound to DNA have been compared to those ...
Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin show a large inte...
The cytotoxicity of Cisplatin (CDDP) is traditionally believed to be cell cycle independent. This ge...
Clonogenic survival of HeLa, Chinese hamster and HaK cells after treatment with a range of cisplatin...
In an attempt to examine the cellular changes associated with cisplatin resistance, we selected a ci...
The aim of this study is to establish anti-tumour potency of the new oral platinum drug JM216 and it...